CONMED’s (CNMD) “Hold” Rating Reaffirmed at Needham & Company LLC

Needham & Company LLC restated their hold rating on shares of CONMED (NYSE:CNMD) in a research note issued to investors on Thursday,Benzinga reports.

A number of other research analysts also recently commented on CNMD. Zacks Research downgraded CONMED from a “hold” rating to a “strong sell” rating in a research note on Thursday, January 1st. Piper Sandler reduced their price target on shares of CONMED from $68.00 to $55.00 and set an “overweight” rating for the company in a report on Thursday, November 6th. Wells Fargo & Company dropped their price objective on shares of CONMED from $57.00 to $47.00 and set an “equal weight” rating on the stock in a report on Thursday, November 6th. Bank of America reduced their target price on shares of CONMED from $65.00 to $52.00 and set a “neutral” rating for the company in a research note on Monday, December 8th. Finally, Weiss Ratings restated a “sell (d+)” rating on shares of CONMED in a research report on Wednesday, January 21st. One equities research analyst has rated the stock with a Buy rating, five have issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the stock has an average rating of “Reduce” and an average price target of $52.83.

CONMED Stock Performance

CNMD stock opened at $37.35 on Thursday. The stock’s 50 day simple moving average is $41.43 and its 200 day simple moving average is $46.43. CONMED has a 12-month low of $35.37 and a 12-month high of $74.70. The firm has a market cap of $1.16 billion, a P/E ratio of 24.74, a P/E/G ratio of 1.74 and a beta of 0.96. The company has a current ratio of 2.10, a quick ratio of 0.95 and a debt-to-equity ratio of 0.85.

CONMED (NYSE:CNMD) last released its quarterly earnings data on Wednesday, January 28th. The company reported $1.43 EPS for the quarter, topping analysts’ consensus estimates of $1.32 by $0.11. The firm had revenue of $373.20 million during the quarter, compared to the consensus estimate of $366.88 million. CONMED had a net margin of 3.42% and a return on equity of 14.36%. The firm’s revenue was up 7.9% on a year-over-year basis. During the same quarter in the previous year, the company posted $1.34 earnings per share. As a group, equities research analysts predict that CONMED will post 4.35 EPS for the current year.

Institutional Trading of CONMED

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Kelleher Financial Advisors bought a new stake in CONMED during the third quarter worth approximately $28,000. CWM LLC lifted its position in shares of CONMED by 352.0% during the 2nd quarter. CWM LLC now owns 791 shares of the company’s stock valued at $41,000 after acquiring an additional 616 shares during the last quarter. Quarry LP boosted its stake in shares of CONMED by 244.8% during the 3rd quarter. Quarry LP now owns 869 shares of the company’s stock worth $41,000 after acquiring an additional 617 shares in the last quarter. Huntington National Bank boosted its stake in shares of CONMED by 111.8% during the 3rd quarter. Huntington National Bank now owns 883 shares of the company’s stock worth $42,000 after acquiring an additional 466 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd acquired a new position in shares of CONMED in the 2nd quarter worth $48,000.

Key CONMED News

Here are the key news stories impacting CONMED this week:

• Positive Sentiment: Q4 revenue and (adjusted) EPS beat consensus and sales rose ~7.9% year‑over‑year, showing recovery in surgical volumes. Strong top‑line performance is a primary driver of the positive headlines. CONMED Corporation Announces Fourth Quarter and Full-Year 2025 Financial Results
• Positive Sentiment: Gross margin improved and surgical (especially orthopedic) sales outperformed, giving management momentum to refocus the business and support 2026 strategy — a constructive signal for future profitability if trends continue. CONMED Stock Up Post Q4 Earnings and Revenue Beat, Gross Margin Up
• Positive Sentiment: Analysts and coverage note that orthopedic strength and a strategic refocus frame a constructive 2026 outlook, which could support medium‑term revenue and margin improvement if execution holds. CNMD Q4 Deep Dive: Ortho Outperformance and Strategic Refocusing Shape 2026 Outlook
• Neutral Sentiment: Wells Fargo nudged its price target slightly higher to $42 and kept an “equal weight” rating — a modest vote of confidence but not an upgrade that would typically spark strong buying. Benzinga
• Negative Sentiment: Some reported GAAP metrics were weaker: third‑party summaries highlighted a much lower GAAP diluted EPS figure and a sharp drop in net income and operating profit year‑over‑year, which raises near‑term earnings quality concerns. That contrast between adjusted and GAAP results is likely prompting investor caution. CONMED Corporation (CNMD) Stock Rises on Q4 2025 Earnings
• Negative Sentiment: Additional headwinds: higher intraday volume and recent insider selling, the stock trading below its 50‑ and 200‑day moving averages, and mixed analyst positions (some holds) have amplified selling pressure despite the beat. Conmed: Q4 Earnings Snapshot

CONMED Company Profile

CONMED Corporation (NYSE: CNMD) is a global medical technology company headquartered in Utica, New York. Founded in 1970, CONMED develops, manufactures and markets a broad portfolio of surgical devices and accessories for minimally invasive procedures. The company’s product line supports surgeons and healthcare providers in specialties including orthopedics, general surgery, gastroenterology and gynecology.

CONMED operates two principal segments: Orthopedics, and Visualization & Energy.